Dermira's (NASDAQ:DERM) topical wipe DRM04 could garner strong physician support due to a clear need for simple and cost-effective hyperhidrosis treatments, experts agreed. Whilst DRM04 may not be ideal for severe hyperhidrosis, its superior efficacy compared with available topical treatments makes it a worthwhile consideration, they said.
As DRM04 is in Phase III trials, it is also far ahead of potential market competitors, so DRM04 will have enough time to establish real world efficacy, experts added. DRM04 off-label use is almost a guarantee and it's twice a day use is not likely to be a compliance issue due to its convenient and elegant application, they said.
DRM04 is estimated to be launched in 2018 and analysts predict peak sales to reach USD 200m. This news service reported on 25 May DRM04's potential Phase III success is considerable given positive Phase IIb results but some elements of the Phase III trial design drew some expert scepticism around patient satisfaction.